Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Xeljanz: The Slow Road To Blockbuster Status

Executive Summary

The oral pill, perhaps best known to investors for failing to live up to initial expectations in rheumatoid arthritis, has found its groove – and new opportunities in psoriatic arthritis and ulcerative colitis are on the horizon.

You may also be interested in...



Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.

Fewer US Market Access Restrictions For Branded I&I Drugs Will Drive Growth

Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.

Pfizer Eyes First-To-Market Opportunity In Alopecia

Inflammation and Immunology Chief Scientific Officer Michael Vincent talked to Scrip about the first positive Phase II data testing a JAK inhibitor for hair loss caused by alopecia areata, next steps for development and the broader I&I portfolio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel